CAR-T Therapy for Solid Tumors: Why Progress Has Been Difficult

How CAR-T works, briefly

CAR-T therapy starts with the patient's own immune cells. NCI describes the steps plainly. Blood is collected and the T cells are separated out. In a laboratory, those cells are engineered to make a chimeric antigen receptor, or CAR, on their surface. The CAR lets them latch onto a specific protein on cancer cells. The cells are then grown until there are hundreds of millions of them and returned to the patient in a single infusion.

NCI notes that the whole process, from the first blood collection to the infusion, currently takes about three to five weeks. Before the infusion, people usually receive chemotherapy to reduce their existing immune cells, which helps the new cells work.

One researcher NCI quotes calls the result "a living drug." Our page on CAR T-cell therapy walks through the process, and what to expect with CAR T-cell therapy covers the practical side.

This page explains federal sources. It is not medical advice and does not suggest a test or treatment.

Where it is approved today

FDA approved the first CAR T-cell therapy in 2017, for children with acute lymphoblastic leukemia. Others followed for adults with blood cancers such as non-Hodgkin lymphoma and multiple myeloma. NCI lists seven CAR T-cell therapies approved for blood cancers.

That is the approved landscape. Solid tumors are not part of it.

Why solid tumors are a harder problem

NCI is direct: compared with the advances in blood cancers, progress on CAR-T for solid tumors has lagged.

Part of the difficulty is finding a target. Researchers have struggled to identify proteins that sit on the surface of solid tumor cells but not on healthy cells, and that also work well as a CAR target. Hit a protein that healthy tissue also carries, and the engineered cells attack the patient.

There is a second problem NCI raises. Solid tumors of the same type can differ a great deal from one patient to another, and even within a single patient. A target present in one part of a tumor may be absent elsewhere.

One research result, read carefully

A 2025 study shows both the promise and the limits.

Researchers tested a CAR-T therapy aimed at a molecule called GD2 in children and young adults with diffuse midline glioma. This is a fast-growing cancer of the brain and spinal cord that usually causes death within a year of diagnosis. NCI notes the only standard therapy is radiation to help control symptoms.

Eleven patients received the treatment. Nine had neurological improvement. Of those, seven had their tumors shrink, in some cases dramatically. Participants lived a median of nearly two years after treatment. Two were still alive past the study's 2.5-year follow-up, and one had no detectable tumor four years after diagnosis.

A study co-investigator said it demonstrates that CAR T cells can have real, meaningful benefit for solid cancers. That is a genuine scientific milestone.

It is also eleven people in an ongoing trial of one rare cancer. Most CAR-T approaches for solid tumors remain available only through research studies.

What a small early trial can and cannot show

• Success in leukemia, lymphoma, or myeloma does not predict success in a solid tumor.
• A response in a small early trial cannot establish long-term benefit, or reveal rare harms.
• Early studies mainly answer whether a treatment is feasible and where the major safety problems are.
• Manufacturing matters. How many enrolled people actually received their cells is part of the result, not a footnote.

Later evidence has to show lasting benefit in more people, and compare the approach with available care where that is possible.

The risks that come with engineered cells

NCI states that like all cancer treatments, CAR T-cell therapies can cause severe side effects.

Two are of particular concern. Cytokine release syndrome is a strong immune reaction to the treatment. The other is a group of neurologic problems known as ICANS, whose signs include confusion, excessive sleepiness, and impaired speech. Infections are among the most common problems, along with a die-off of antibody-producing B cells.

These are managed in specialized centers with close monitoring. They are part of what any headline about a cell therapy is describing, whether or not it says so. Our overview of immunotherapy sets these treatments in context.

Questions about a solid-tumor CAR-T headline

• What tumor target does the CAR recognize, and where else does that target appear?
• How many people were treated, and was the study designed mainly for safety?
• How long were participants followed?
• Is this available outside a clinical trial?
• How are immune and neurologic side effects monitored?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.